SNCA and Parkinson disease: Indeed, analysis of dopaminergic components, and of α-synuclein levels support the designation of the samples, inasmuch as these components were altered as might be expected in PD samples, and likewise, analysis of GCase activity and levels were consistent with the genetic designation of the PD-GBA samples.